Redeye has revised its near-term estimates and valuation following the Q4 report, which showed resil...
Redeye updates its estimates and valuation following MedCap releasing its Q4 2024 report.
Redeye's view is that Lagercrantz reported another strong quarter in a challenging market.
Minor positive estimate revisions Margin expansion to be increasingly driven by scale Trading at '25...
Redeye comments on today’s news that the European Commission has asked EMA’s CHMP to consider two ad...
Redeye changes its Base Case and forecasts following a strong end to a solid 2024 from Addnode.
Redeye comments on the news that IRLAB has presented positive top-line data from the phase I study i...
Q4: -6% org. sales growth, 2% adj. EBITA growth, strong cash flow '25e-'26e adj.
Redeye provides its initial take on Lifco’s Q4 2024 report, which featured a slight sales beat and m...
Redeye shares its initial take on Kontigo Care’s Q4 2024 results, which showed sales and monthly rec...
Redeye retains its positive view on Lagercrantz following a Q3 report in-line with our estimates.
Vitrolife delivered a consecutive positive organic growth recovery with 6% organic growth in constan...
Apathy drug candidate completed Ph 1 in elderly adults Positive PK, safety and tolerability data con...
Redeye provides its initial take on MedCap’s Q4 2024 report, which came in broadly below our initial...
Redeye states that Enea showed solid sales growth while EBITDA margin were slightly below expectatio...
Sales -3%, adj. EBIT -2m vs. ABGSCe Temporary incoming delivery delays push cash flow into Q1 Optimi...
Diagonal Bio är ett bioteknikbolag som utvecklar och säljer en analysplattform för identifiering av ...
Redeye finetunes its forecasts for 2025 and beyond following Fortnox’s price increases.
Vitrolife continues stabilise its growth rate and is approaching high single-digit growth.
Redeye comments on Enea’s Q4 2024 report, where sales met Redeye Research estimates (RRe) in Enea’s ...
